B-intervention	0	7	Dietary
I-intervention	8	16	flaxseed
O	17	23	alters
O	24	29	tumor
O	30	40	biological
O	41	48	markers
O	49	51	in
O	52	66	postmenopausal
O	67	73	breast
O	74	80	cancer
O	80	81	.

O	82	90	Flaxseed
O	90	91	,
O	92	95	the
O	96	103	richest
O	104	110	source
O	111	113	of
O	114	123	mammalian
O	124	130	lignan
O	131	141	precursors
O	141	142	,
O	143	146	has
O	147	157	previously
O	158	162	been
O	163	168	shown
O	169	171	to
O	172	178	reduce
O	179	182	the
O	183	189	growth
O	190	192	of
O	193	199	tumors
O	200	202	in
O	203	207	rats
O	207	208	.

O	209	213	This
O	214	219	study
O	220	228	examined
O	228	229	,
O	230	232	in
O	233	234	a
O	235	245	randomized
O	246	252	double
O	252	253	-
O	253	258	blind
O	259	266	placebo
O	266	267	-
O	267	277	controlled
O	278	286	clinical
O	287	292	trial
O	292	293	,
O	294	297	the
O	298	305	effects
O	306	308	of
O	309	316	dietary
O	317	325	flaxseed
O	326	328	on
O	329	334	tumor
O	335	345	biological
O	346	353	markers
O	354	357	and
O	358	365	urinary
O	366	372	lignan
O	373	382	excretion
O	383	385	in
B-eligibility	386	400	postmenopausal
I-eligibility	401	409	patients
I-eligibility	410	414	with
I-eligibility	415	420	newly
I-eligibility	421	430	diagnosed
I-eligibility	431	437	breast
I-eligibility	438	444	cancer
O	444	445	.

O	446	454	Patients
O	455	459	were
O	460	470	randomized
O	471	473	to
O	474	479	daily
O	480	486	intake
O	487	489	of
O	490	496	either
O	497	498	a
O	499	501	25
O	502	503	g
O	504	512	flaxseed
O	512	513	-
O	513	523	containing
O	524	530	muffin
O	531	532	(
O	532	533	n
O	534	535	=
B-intervention-participants	536	538	19
O	538	539	)
O	540	542	or
O	543	544	a
B-control	545	552	control
I-control	553	554	(
I-control	554	561	placebo
I-control	561	562	)
O	563	569	muffin
O	570	571	(
O	571	572	n
O	573	574	=
B-control-participants	575	577	13
O	577	578	)
O	578	579	.

O	580	582	At
O	583	586	the
O	587	591	time
O	592	594	of
O	595	604	diagnosis
O	605	608	and
O	609	614	again
O	615	617	at
O	618	628	definitive
O	629	636	surgery
O	636	637	,
O	638	643	tumor
O	644	650	tissue
O	651	654	was
O	655	663	analyzed
O	664	667	for
O	668	671	the
O	672	676	rate
O	677	679	of
O	680	685	tumor
O	686	690	cell
O	691	704	proliferation
O	705	706	(
B-outcome-Measure	706	708	Ki
I-outcome-Measure	708	709	-
I-outcome-Measure	709	711	67
I-outcome-Measure	712	720	labeling
I-outcome-Measure	721	726	index
O	726	727	,
O	728	735	primary
O	736	739	end
O	740	745	point
O	745	746	)
O	746	747	,
B-outcome-Measure	748	757	apoptosis
O	757	758	,
B-outcome-Measure	759	760	c
I-outcome-Measure	760	761	-
I-outcome-Measure	761	766	erbB2
I-outcome-Measure	767	777	expression
O	777	778	,
O	779	782	and
B-outcome-Measure	783	791	estrogen
I-outcome-Measure	792	795	and
I-outcome-Measure	796	808	progesterone
I-outcome-Measure	809	817	receptor
I-outcome-Measure	818	824	levels
O	824	825	.

O	826	832	Twenty
O	832	833	-
O	833	837	four
O	837	838	-
O	838	842	hour
O	843	848	urine
O	849	856	samples
O	857	861	were
O	862	870	analyzed
O	871	874	for
O	875	882	lignans
O	882	883	,
O	884	887	and
O	888	889	3
O	889	890	-
O	890	893	day
O	894	898	diet
O	899	906	records
O	907	911	were
O	912	921	evaluated
O	922	925	for
O	926	939	macronutrient
O	940	943	and
O	944	951	caloric
O	952	958	intake
O	958	959	.

B-outcome	960	964	Mean
I-outcome	965	974	treatment
I-outcome	975	980	times
O	981	985	were
B-cv-cont-mean	986	988	39
O	989	992	and
B-iv-cont-mean	993	995	32
I-iv-cont-mean	996	1000	days
O	1001	1003	in
O	1004	1007	the
O	1008	1015	placebo
O	1016	1019	and
O	1020	1028	flaxseed
O	1029	1035	groups
O	1035	1036	,
O	1037	1049	respectively
O	1049	1050	.

B-outcome	1051	1061	Reductions
I-outcome	1062	1064	in
I-outcome	1065	1067	Ki
I-outcome	1067	1068	-
I-outcome	1068	1070	67
I-outcome	1071	1079	labeling
I-outcome	1080	1085	index
O	1086	1087	(
O	1087	1089	34
O	1089	1090	.
O	1090	1091	2
O	1091	1092	%
O	1092	1093	;
O	1094	1095	P
O	1096	1097	=
O	1098	1099	0
O	1099	1100	.
O	1100	1103	001
O	1103	1104	)
O	1105	1108	and
O	1109	1111	in
B-outcome	1112	1113	c
I-outcome	1113	1114	-
I-outcome	1114	1119	erbB2
I-outcome	1120	1130	expression
O	1131	1132	(
O	1132	1134	71
O	1134	1135	.
O	1135	1136	0
O	1136	1137	%
O	1137	1138	;
O	1139	1140	P
O	1141	1142	=
O	1143	1144	0
O	1144	1145	.
O	1145	1148	003
O	1148	1149	)
O	1150	1153	and
O	1154	1156	an
O	1157	1165	increase
O	1166	1168	in
B-outcome	1169	1178	apoptosis
O	1179	1180	(
O	1180	1182	30
O	1182	1183	.
O	1183	1184	7
O	1184	1185	%
O	1185	1186	;
O	1187	1188	P
O	1189	1190	=
O	1191	1192	0
O	1192	1193	.
O	1193	1196	007
O	1196	1197	)
O	1198	1202	were
O	1203	1211	observed
O	1212	1214	in
O	1215	1218	the
O	1219	1227	flaxseed
O	1227	1228	,
O	1229	1232	but
O	1233	1236	not
O	1237	1239	in
O	1240	1243	the
O	1244	1251	placebo
O	1252	1257	group
O	1257	1258	.

O	1259	1261	No
O	1262	1273	significant
O	1274	1285	differences
O	1286	1288	in
B-outcome	1289	1296	caloric
I-outcome	1297	1300	and
I-outcome	1301	1314	macronutrient
I-outcome	1315	1321	intake
O	1322	1326	were
O	1327	1331	seen
O	1332	1339	between
O	1340	1346	groups
O	1347	1350	and
O	1351	1358	between
O	1359	1362	pre
O	1362	1363	-
O	1364	1367	and
O	1368	1381	posttreatment
O	1382	1389	periods
O	1389	1390	.

O	1391	1392	A
O	1393	1404	significant
O	1405	1413	increase
O	1414	1416	in
B-outcome	1417	1421	mean
I-outcome	1422	1429	urinary
I-outcome	1430	1436	lignan
I-outcome	1437	1446	excretion
O	1447	1450	was
O	1451	1459	observed
O	1460	1462	in
O	1463	1466	the
O	1467	1475	flaxseed
O	1476	1481	group
O	1482	1483	(
O	1483	1484	1
O	1484	1485	,
O	1485	1488	300
O	1488	1489	%
O	1489	1490	;
O	1491	1492	P
O	1493	1494	<
O	1495	1496	0
O	1496	1497	.
O	1497	1499	01
O	1499	1500	)
O	1501	1509	compared
O	1510	1514	with
O	1515	1522	placebo
O	1523	1531	controls
O	1531	1532	.

O	1533	1536	The
O	1537	1542	total
O	1543	1549	intake
O	1550	1552	of
O	1553	1561	flaxseed
O	1562	1565	was
O	1566	1576	correlated
O	1577	1581	with
O	1582	1589	changes
O	1590	1592	in
O	1593	1594	c
O	1594	1595	-
O	1595	1600	erbB2
O	1601	1606	score
O	1607	1608	(
O	1608	1609	r
O	1610	1611	=
O	1612	1613	-
O	1613	1614	0
O	1614	1615	.
O	1615	1618	373
O	1618	1619	;
O	1620	1621	P
O	1622	1623	=
O	1624	1625	0
O	1625	1626	.
O	1626	1629	036
O	1629	1630	)
O	1631	1634	and
O	1635	1644	apoptotic
O	1645	1650	index
O	1651	1652	(
O	1652	1653	r
O	1654	1655	=
O	1656	1657	0
O	1657	1658	.
O	1658	1661	495
O	1661	1662	;
O	1663	1664	P
O	1665	1666	<
O	1667	1668	0
O	1668	1669	.
O	1669	1672	004
O	1672	1673	)
O	1673	1674	.

O	1675	1682	Dietary
O	1683	1691	flaxseed
O	1692	1695	has
O	1696	1699	the
O	1700	1709	potential
O	1710	1712	to
O	1713	1719	reduce
O	1720	1725	tumor
O	1726	1732	growth
O	1733	1735	in
O	1736	1744	patients
O	1745	1749	with
O	1750	1756	breast
O	1757	1763	cancer
O	1763	1764	.
